New research indicates that patients who come off blockbuster weight-loss injections like Mounjaro or Wegovy can put back on lost weight far faster than those who halt traditional diet and exercise regimens.
Published data in a major medical journal demonstrates that while overweight individuals frequently drop substantial amounts of their total mass while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month after stopping.
"Users purchasing such treatments must be cognizant of the potential of quick rebound weight gain when the treatment ends," cautioned researcher Dr. Susan Jebb.
This pace of regain means a reversion to starting mass within about 18 months.
Weighing Approaches
The research, which reviewed dozens of trials involving thousands of participants, contrasted the results of GLP-1 agonists with conventional dieting.
Researchers point out that individuals who lose weight through dieting generally experience a slower weight regain—perhaps 0.1 kg a month—once they finish.
The Reason for the Fast Regain
Experts propose the way of the drugs is key to understanding the heightened rebound.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Sustained high doses of GLP-1 concentrations several times higher than normal could lead to the system to generate a reduced amount of its endogenous hormone, and could lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' means hunger is no longer kept in check, making binge eating a significant risk."
A Lifelong Disease?
The NHS suggest the injections for people with weight-linked health risks, alongside prescribed lifestyle changes.
Professionals say that, due to the significant potential of weight regain, the treatment might need to be life-long.
This opinion is reinforced by drug manufacturers, who state that the findings "highlight the persistent character of obesity," comparing it to managing diseases like high blood pressure.
User Testimonies
People who have come off the medication explain a intense resurgence of appetite.
"It felt as if something that goes on and you become ravenous," described a patient.
This difficulty is exacerbated if users have not developed lasting lifestyle or habit modifications during therapy.
Growing Adoption
Recent estimates show that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.
- Adoption is more common among women than males.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Finally, experts caution that while GLP-1 drugs are effective agents for weight loss, they are not a standalone solution and long-term success relies on integrated lifestyle management.
